OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd. furnished this Form 6-K on May 20, 2022, under Commission File Number 001-41386. The filing reports that the company issued a United Kingdom news service announcement concerning a dealing by a person discharging managerial responsibilities (PDMR).
Financial Metrics and Capital Position
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes Versus Prior Period
No financial or operational changes versus a prior comparable period are disclosed. The reported event is a PDMR dealing; the transaction details are not included in the provided filing text.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no guidance, outlook, management commentary, risk updates, contingencies, or unusual accounting items. Exhibit 99.1 is identified as a news service announcement dated May 20, 2022, but its substantive contents are not included in the provided text.
Key Facts for Investor Verification
- Review Exhibit 99.1 to identify the PDMR, security involved, transaction type, number of securities, price, and transaction date.
- Confirm whether the dealing changed the relevant individual's ownership or voting interest.
- Verify the announcement's relationship to the company's broader capital structure and any outstanding equity awards.
- Note that the Form 6-K states the attached information is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference unless expressly stated.